Keywords: UCB, Financial results 2011
UCB sees strong showing from core products in 2011
Article | 05 March 2012
Belgian drugmaker UCB (UCB: BR) announced consolidated 2011 financial results, showing that revenue increased just 1% to 3.25 billion euros ($4.37 billion). Net sales ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Is failure to adopt business process management putting the pharma industry at risk?
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
